655 related articles for article (PubMed ID: 15541325)
21. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera.
Marchioli R; Finazzi G; Landolfi R; Kutti J; Gisslinger H; Patrono C; Marilus R; Villegas A; Tognoni G; Barbui T
J Clin Oncol; 2005 Apr; 23(10):2224-32. PubMed ID: 15710945
[TBL] [Abstract][Full Text] [Related]
22. Aspirin-responsive painful red, blue, black toe, or finger syndrome in polycythemia vera associated with thrombocythemia.
Michiels JJ; Berneman Z; Schroyens W; van Urk H
Ann Hematol; 2003 Mar; 82(3):153-9. PubMed ID: 12634947
[TBL] [Abstract][Full Text] [Related]
23. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.
Dingli D; Schwager SM; Mesa RA; Li CY; Dewald GW; Tefferi A
Cancer; 2006 May; 106(9):1985-9. PubMed ID: 16568439
[TBL] [Abstract][Full Text] [Related]
24. Highly reduced survival in essential thrombocythemia and polycythemia vera patients with vascular complications during follow-up.
Ahlstrand E; Samuelsson J; Lindgren M; Pettersson H; Liljeholm M; Ravn-Landtblom A; Scheding S; Andréasson B
Eur J Haematol; 2020 Mar; 104(3):271-278. PubMed ID: 31863513
[TBL] [Abstract][Full Text] [Related]
25. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms.
Vannucchi AM; Masala G; Antonioli E; Chiara Susini M; Guglielmelli P; Pieri L; Maggi L; Caini S; Palli D; Bogani C; Ponziani V; Pancrazzi A; Annunziato F; Bosi A
Cancer Epidemiol Biomarkers Prev; 2009 Jul; 18(7):2068-73. PubMed ID: 19531676
[TBL] [Abstract][Full Text] [Related]
26. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Landolfi R; Di Gennaro L; Novarese L; Patrono C
Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
[TBL] [Abstract][Full Text] [Related]
27. 20+ yr without leukemic or fibrotic transformation in essential thrombocythemia or polycythemia vera: predictors at diagnosis.
Tefferi A; Gangat N; Wolanskyj AP; Schwager S; Pardanani A; Lasho TL; Mesa R; McClure RF; Li CY; Hanson CA
Eur J Haematol; 2008 May; 80(5):386-90. PubMed ID: 18221390
[TBL] [Abstract][Full Text] [Related]
28. Clinical predictors of outcome in MPN.
Passamonti F; Maffioli M; Merli M; Ferrario A; Caramazza D
Hematol Oncol Clin North Am; 2012 Oct; 26(5):1101-16. PubMed ID: 23009940
[TBL] [Abstract][Full Text] [Related]
29. Is life expectancy of polycythemia vera patients clearly different from that of the general population?
Kiladjian JJ; Bernard JF; Fenaux P
Am J Med; 2005 May; 118(5):565; author reply 565-6. PubMed ID: 15866263
[No Abstract] [Full Text] [Related]
30. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
[TBL] [Abstract][Full Text] [Related]
31. Essential thrombocythemia following polycythemia vera: an unusual sequence.
Randi ML; Barbone E; Zerbinati P; Soini B; Rossi C; Girolami A
J Med; 1996; 27(5-6):363-8. PubMed ID: 9151204
[TBL] [Abstract][Full Text] [Related]
32. Association of monoclonal gammopathy and polycythemia vera or essential thrombocythemia: study of a large cohort of patients.
Randi ML; Tison T; Ruzzon E; Pacquola E; Girolami A
Ann Hematol; 2003 Apr; 82(4):214-7. PubMed ID: 12707723
[TBL] [Abstract][Full Text] [Related]
33. Erythromelalgia: a pathognomonic microvascular thrombotic complication in essential thrombocythemia and polycythemia vera.
van Genderen PJ; Michiels JJ
Semin Thromb Hemost; 1997; 23(4):357-63. PubMed ID: 9263352
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic criteria and prognosis in polycythemia vera and essential thrombocythemia.
Murphy S
Semin Hematol; 1999 Jan; 36(1 Suppl 2):9-13. PubMed ID: 9930551
[TBL] [Abstract][Full Text] [Related]
35. Risk-adapted therapy in essential thrombocythemia and polycythemia vera.
Finazzi G; Barbui T
Blood Rev; 2005 Sep; 19(5):243-52. PubMed ID: 15963833
[TBL] [Abstract][Full Text] [Related]
36. The rate of progression to polycythemia vera or essential thrombocythemia in patients with erythrocytosis or thrombocytosis.
Ruggeri M; Tosetto A; Frezzato M; Rodeghiero F
Ann Intern Med; 2003 Sep; 139(6):470-5. PubMed ID: 13679323
[TBL] [Abstract][Full Text] [Related]
37. [The risk factors for thrombosis, myelofibrosis and leukemia transformation in patients with polycythemia vera].
Bai J; Xue YP; Ye L; Yao JF; Zhou CL; Qian LS; Yang RC; Li HY; Zhang HY; Shao ZH
Zhonghua Xue Ye Xue Za Zhi; 2007 Oct; 28(10):685-8. PubMed ID: 18399175
[TBL] [Abstract][Full Text] [Related]
38. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
39. Therapy for polycythemia vera and essential thrombocythemia is driven by the cardiovascular risk.
Barbui T; Finazzi G
Semin Thromb Hemost; 2007 Jun; 33(4):321-9. PubMed ID: 17525889
[TBL] [Abstract][Full Text] [Related]
40. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation.
Gangat N; Strand J; Li CY; Wu W; Pardanani A; Tefferi A
Br J Haematol; 2007 Aug; 138(3):354-8. PubMed ID: 17614822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
